The global sales of non-vascular stents are estimated to be worth USD 1,408.7 million in 2025 and anticipated to reach a value of USD 2,338.8 million by 2035. Sales are projected to rise at a CAGR of 5.2% over the forecast period between 2025 and 2035. The revenue generated by non-vascular stents in 2024 was USD 1,339.1 million.
Increasing cases of biliary strictures are the primary growth factor for the non-vascular stents market. Biliary strictures generally caused by various conditions such as tumors, gallstones, and inflammatory diseases. All these conditions are raising the demand for effective solutions in the treatment process. Non-vascular stents are a key element for de-obstruction and bile flow improvement.
Advancements in stent technology, with biodegradable and drug-eluting stents, contribute to the further expansion of the market by enabling improved safety and efficacy. With healthcare providers increasingly resorting to minimally invasive procedures for the management of biliary strictures, this market is set to continue its growth in line with clinical needs.
Global Non-Vascular Stents Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2024 | USD 1,339.1 million |
| Estimated Size, 2025 | USD 1,408.7 million |
| Projected Size, 2035 | USD 2,338.8 million |
| Value-based CAGR (2025 to 2035) | 5.2% |
The rise in the prevalence of conditions like pancreatic and bile duct cancers, which frequently cause biliary strictures, has significantly driven the demand for biliary stents. According to the Global Cancer Observatory (GLOBOCAN), cases of pancreatic and liver cancers are expected to rise globally, contributing to a corresponding increase in stent placements.
Additionally, advanced stent designs, like self-expanding and drug-eluting stents, which have made procedures involving biliary stenting better in terms of efficacy and safety, reduce the complications, outcomes, and improvement in patient results.
Besides, an older population that tends to suffer from biliary conditions more easily coupled with increased medical infrastructure in the developing economies means that biliary strictures lead to an escalating market for non-vascular stents.
In summary, the rising incidence of biliary strictures, driven by underlying conditions and improved treatment modalities, underscores its importance as a market driver for non-vascular stents.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The below table presents the expected CAGR for the global non-vascular stents market over several semi-annual periods spanning from 2025 to 2035. In the first half (H1) of the decade from 2024 to 2035, the business is predicted to surge at a CAGR of 5.9%, followed by a slightly lower growth rate of 5.6% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 5.9% (2024 to 2034) |
| H2 | 5.6% (2024 to 2034) |
| H1 | 5.2% (2025 to 2035) |
| H2 | 4.7% (2025 to 2035) |
Moving into the subsequent period, from H1 2025 to H2 2035, the CAGR is projected to decrease slightly to 5.2% in the first half and decrease moderately at 4.7% in the second half. In the first half (H1) the market witnessed a decrease of 70.00 BPS while in the second half (H2), the market witnessed an increase of 90.00 BPS.
Innovations in Product Design and Materials Is Driving the Growth for Non-Vascular Stents Market.
Advanced materials involving nitinol, cobalt-chromium, and polymer composites have revolutionized the stent durability, flexibility, and biocompatibility. These result in better adaptability to the anatomical structure, reduced risks of migration or perforation, and comfort for the patient.
For example, nitinol’s shape-memory property allows stents to expand upon placement and conform to dynamic anatomical changes, particularly in gastrointestinal or biliary applications.
Additionally, novel designs such as fully covered stents and self-expanding stents have improved the treatment of strictures and obstructions. Fully covered stents prevent tissue ingrowth, reducing complications like restenosis, while self-expanding stents enhance procedural precision and adaptability in complex cases. These innovations address the limitations of traditional designs, driving broader adoption among healthcare providers.
An example is the WallFlex Biliary RX Stent System by Boston Scientific, which combines a self-expanding nitinol structure with a fully covered design. This stent effectively manages biliary obstructions caused by malignancies while reducing migration risks. Another example is the Zilver PTX Stent by Cook Medical, which integrates nitinol with drug-eluting technology, ensuring both structural support and localized drug delivery.
In summary, continuous advancements in materials and design improve stent efficacy and safety, fueling the expansion of the non-vascular stents market.
Advancement In Delivery Systems Is a Significant Driver for The Growth of the Non-Vascular Stents Market.
Advanced delivery systems facilitate smooth stent placement. It simplifies the process of stent placement and contributes to reducing complexity and probability of error. This hydrophilic property reduces friction while passing through, and it ensures less trauma to the patient during the process.
Radiopaque markers provide accurate vision by ensuring that surgeons visualize their pathways under imaging, thereby facilitating ideal positioning during complex anatomical locations.
Advances in this direction reduce the likelihood of complications, decrease procedure time, and better overall patient outcomes; therefore, the use of non-vascular stents is the preferred option by both healthcare providers and patients.
This ease of use and the enhanced safety profile has greatly increased the adoption of non-vascular stents for the treatment of biliary, esophageal, and colonic obstructions.
Examples of innovation in delivery system design include Boston Scientific's WallFlex Biliary RX Stent System, offering a controlled release delivery mechanism designed for precise placement, and the Hanarostent Esophagus by M.I. Tech, which delivers through a distinct delivery system devised for smooth implantation in an esophageal stricture. These systems prove how advanced technology is tailored specifically to meet needs in clinical life.
In conclusion, minimally invasive deployment technologies not only enhance the usability and effectiveness of non-vascular stents but also reduce procedural risks, contributing to their growing adoption and driving market expansion globally.
Drug-Eluting Stents Which Release Therapeutic Agents Locally Are Gaining Traction in The Non-Vascular Stents Market.
Drug-eluting non-vascular stents are the most promising in terms of the market opportunity as they serve the dual purpose of maintaining luminal patency and delivering therapeutic agents directly to the site of obstruction.
These stents release drugs locally, which minimizes systemic side effects and effectively addresses inflammation, restenosis, or infections associated with malignant and benign obstructions. This localized drug delivery is particularly advantageous for patients with malignancies, where tumor progression can be mitigated alongside the mechanical relief of blockages.
One of the examples is the Cook Medical Zilver PTX Drug-Eluting Peripheral Stent. It is developed to treat blockages in the biliary duct. This drug-eluting stent releases paclitaxel, which is a drug known for its anti-proliferative properties and reduces the chance of restenosis while allowing bile flow to be maintained. Its proven efficacy in challenging conditions has positioned it as a leader in the biliary stent market.
An example of this is the Boston Scientific WallFlex Biliary RX Fully Covered Stent System with Anti-Reflux Valve, a drug-eluting mechanism designed for malignant biliary strictures. It prevents the re-narrowing of bile ducts while incorporating anti-reflux technology that improves the outcomes of the patients and reduces complications.
In summary, drug-eluting non-vascular stents present a lucrative opportunity in the market, driven by their advanced therapeutic capabilities and effectiveness in managing complex conditions. Their dual-action mechanism positions them as a transformative solution in interventional medicine.
Risk of Infection and Biofilm Formation Emerging as Significant Growth Barrier for Non-Vascular Stents Market Growth
Infection and biofilm formation pose a serious barrier to growth in the non-vascular stents market. Infection related to the placement of a stent can lead to serious complications such as extended hospitalization, reoperation, and increased health costs. These risks might keep both healthcare providers and patients away from stent-based treatments, hence limiting the market potential.
Additionally, particular concern is biofilm formation, which involves the attachment of bacteria to the surface of the stent, multiplication, and the formation of a protective layer that is quite hard to eradicate.
This phenomenon increases not only the chances of infection but also complicates the treatment outcomes. Biofilms have been shown to form on stents rapidly, especially in those that have been in place for a long time, leading to chronic infections and other complications.
Moreover, heightened awareness of such risks might make healthcare providers more prudent in the prescription of non-vascular stents, especially in sensitive patient groups. Such prudence might delay the use of new stent technologies, even while new technologies have been developed to reduce infection risks.
Moreover, the higher rate of complications will also invite stricter regulatory requirements for the approval of new products, increasing the time and further costs of bringing new stent solutions to the market.
Thus, it becomes difficult for the manufacturer to develop effective and safe products that could address these issues while remaining economically viable for widespread use. Therefore, the double threats of infection and biofilm formation substantially hinder the growth trajectory of the non-vascular stents market.
The global non-vascular stents industry recorded a CAGR of 4.6% during the historical period between 2020 and 2024. The growth of non-vascular stents industry was positive as it reached a value of USD 1,339.1 million in 2024 from USD 1,087.4 million in 2020.
The non-vascular stents market has evolved significantly, showcasing robust growth driven by increasing incidences of obstructive diseases and advancements in minimally invasive procedures.
Traditional technologies were primarily focused on metallic stents, including bare-metal and partially-covered stents, which were effective but had limitations in biocompatibility and long-term efficacy. These earlier stents often caused tissue ingrowth and required repeated interventions.
The industry is moving towards use of more advanced materials, such as nitinol and fully-covered stents, allowing for greater flexibility, biocompatibility, and less tissue adhesion. For temporary applications, biodegradable stents have become increasingly in use, making retrieval surgeries almost obsolete.
Emerging trends emphasize the integration of smart technologies, such as drug-eluting stents designed to release therapeutic agents locally, and radiopaque markers for improved imaging.
Furthermore, personalized stent designs using 3D printing are expected to address unique anatomical challenges effectively. The rising focus on endoscopic deployment techniques has also significantly improved patient outcomes.
Geographically, the market is witnessing strong growth in developing regions like Asia Pacific due to increasing healthcare accessibility. Looking ahead, innovations in bioengineered coatings and AI-enabled placement techniques are poised to redefine the future of non-vascular stents, enhancing precision and reducing complications.
Tier 1 companies comprise market leaders with a significant market share of 58.9% in global market. These companies engage in strategic partnerships and acquisitions to expand their product portfolios and access cutting-edge technologies.
Additionally, they emphasize extensive clinical trials to validate the efficacy and safety of their products. Prominent companies in tier 1 include Boston Scientific Corporation, Becton, Dickinson and Company (BD), Medtronic and Cook Medical.
Tier 2 companies include mid-size players having presence in specific regions and highly influencing the local market and holds around 21.9% market share. They typically pursue partnerships with multispecialty hospitals and research organizations to leverage emerging technologies and expedite product development.
These companies often emphasize agility and adaptability, allowing them to quickly bring new products to market, additionally targeting specific types medical needs. Additionally, they focus on cost-effective production methods to offer competitive pricing. Prominent companies in tier 2 include CONMED Corporation, ELLA - CS, s.r.o., Glaukos Corporation and HOBBS MEDICAL, INC.
Finally, Tier 3 companies, such as Micro-Tech (Nanjing) Co., Ltd. and Merit Medical Systems. They specialize in specific products and cater to niche markets, adding diversity to the industry.
Overall, while Tier 1 companies are the primary drivers of the market, Tier 2 and 3 companies also make significant contributions, ensuring the non-vascular stents sales remains dynamic and competitive.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The section below covers the industry analysis for the non-vascular stents market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle Ease & Africa, is provided.
The United States is anticipated to remain at the forefront in North America, with higher market share through 2035. In South Asia & Pacific, India is projected to witness a CAGR of 7.3% by 2035.
| Countries | Value CAGR (2025 to 2035) |
|---|---|
| United States | 3.2% |
| Germany | 4.4% |
| China | 6.0% |
| France | 3.8% |
| India | 7.3% |
| Spain | 5.7% |
| Australia & New Zealand | 6.5% |
| South Korea | 6.0% |
United States. non-vascular stents market is poised to exhibit a CAGR of 3.2% between 2025 and 2035. Currently, it holds the highest share in the North American market.
Companies with robust market presence like Medtronic, Boston Scientific, and Cook Medical dominate the market share and enhance growth prospects of non-vascular stents in the USA market.
Due to this heavy investment on research and development (R&D) activity, new and improved technologies of products enhance its position among consumers and have positive implications for better patient outcome as far as advanced technologies, drug-eluting and biodegradable stent.
The other reason is that these companies exploit their huge distribution networks and strong relationships with health care providers for widespread acceptance of their products. The competitive landscape forces constant innovation and fast reaction to the demands of the market, which will help the environment flourish for new technologies.
The USA market reaps the advantages of diverse, quality non-vascular stents meeting the increased demand for minimally invasive procedures to address several chronic conditions effectively. This interaction of innovation with the market consolidates the position of the USA at the top in the market for non-vascular stents.
China’s non-vascular stents market is poised to exhibit a CAGR of 6.0% between 2025 and 2035. Currently, it holds the highest share in the East Asia market, and the trend is expected to continue during the forecast period.
A high geriatric population in China is the key growth driver in the non-vascular stents market. Aged patients are more likely to be diagnosed with conditions like gastrointestinal, biliary, and tracheobronchial obstructions that necessitate the application of non-vascular stents for treatment.
The population change has seen the increased demand for minimally invasive procedures among aged patients, especially since these treatments are characterized by less time for recovery and a decreased risk of surgical complications.
China's healthcare landscape is transforming itself to meet the needs of the aging population and has been seen to provide ample access to more diagnostic and therapeutic technologies.
There is an ever-increasing rise in age-related diseases, resulting in heavy investment in medical infrastructure to make all these technologies readily available and affordable. This results in a high geriatric demographic in China becoming a significant enabler for growth, not just in terms of adoption but also innovation of non-vascular stents in China.
India non-vascular stents market is poised to exhibit a CAGR of 7.3% between 2025 and 2035. Currently, it holds the highest share in the South Asia & Pacific market, and the trend is expected to continue during the forecast period.
The increasing burden of diseases that require stent implantation is one of the key drivers for the non-vascular stents market in India. The increasing prevalence of gastrointestinal obstructions, biliary tract blockages, and urinary disorders increases the need for effective treatment options.
Such factors include dietary habits, high obesity levels, and an increasing percentage of geriatric population lead to a rising trend in such diseases, which further calls for the use of non-vascular stents to reduce symptoms and improve patient outcome.
The treatment preference now shifts toward less invasive, non-vascular stents as it results in short recovery periods with lower complication risk, mainly in chronic diseases. Availability of the diagnostic equipment across all hospitals and health facilities further improves the detection of obstructive diseases in early stages, further adding to demand.
The high prevalence of diseases within the population also has been found to provide huge market potential hence this parameter drives up the use and manufacturing of non-vascular stents throughout India.
The section contains information about the leading segments in the industry. By product type, the biliary stents segment is expected to hold the highest market share of 34.5% in 2025.
| By Disease Type | Biliary Stents |
|---|---|
| Value Share (2025) | 34.5% |
Biliary stents are leading non-vascular stents because the incidence of biliary obstruction by gallstones, pancreatic cancer, and bile duct strictures is very high.
These stents are very important in the care of patients, especially for the palliation and minimally invasive procedures in restituting the flow of bile and symptoms that are brought by obstruction. In many ways, the management of both malignant and benign obstructions places them as core in non-vascular applications.
Improvements in technology, in terms of self-expanding, drug-eluting, and fully-covered stents, have improved their effectiveness and longevity, pushing the number of their adoption. In addition, greater demand for endoscopic procedures, completely dependent on biliary stents, further helped to consolidate them as a mainstay of the market.
There is also a growing awareness of the early diagnosis and treatment of biliary conditions, along with increased access to advanced healthcare infrastructure, especially in emerging markets, that contributes to the strong demand for biliary stents, which makes them the leading product type in the market.
| By Technology | Self-Expanding Stents |
|---|---|
| Value Share (2025) | 42.6% |
These stents are designed to automatically expand upon deployment, ensuring that the obstructed pathway is maintained under consistent pressure. Conforming to irregular anatomies and dynamic physiological conditions, they have been the preferred option for complex cases in biliary, esophageal, and bronchial applications.
The development of new materials, including nitinol, that have improved flexibility, durability, and biocompatibility also promotes the widespread use of self-expanding stents. They are particularly beneficial for minimally invasive procedures because they reduce trauma at the time of placement and result in better patient outcomes.
Healthcare providers rely more on the self-expanding stents based on their performance in the long term and delivery, even under difficult anatomies. With more versatility, their increasing demand for effective yet patient-friendly treatments cements them as the superior technology in this non-vascular stents market.
The market players are using strategies to stay competitive, such as product differentiation through innovative formulations, strategic partnerships with healthcare providers for distribution.
Another key strategic focus of these companies is to actively look for strategic partners to bolster their product portfolios and expand their global market presence.
Recent Industry Developments in Non-Vascular Stents Market
In terms of product type, the industry is divided into- biliary stents, esophageal stents, colonic stents, bronchial stents and ureteral stents.
In terms of material, the industry is segregated into- metal stents, polymer stents and hybrid stents.
In terms of application, the industry is segregated into- malignant obstructions, benign obstructions and palliative care.
In terms of technology, the industry is segregated into- self-expanding stents, balloon-expandable stents, drug-eluting stents, biodegradable/bioresorbable stents and anti-reflux stents.
In terms of end user, the industry is segregated into- hospitals, specialty clinics and ambulatory surgical centers (ASCs).
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia and Middle East and Africa (MEA) have been covered in the report.
The global non-vascular stents market is projected to witness CAGR of 5.2% between 2025 and 2035.
The global non-vascular stents industry stood at USD 1,339.1 million in 2024.
The global non-vascular stents market is anticipated to reach USD 2,338.8 million by 2035 end.
India is set to record the highest CAGR of 7.3% in the assessment period.
The key players operating in the global non-vascular stents market include Boston Scientific Corporation, Becton, Dickinson and Company (BD), Medtronic, Cook Medical, CONMED Corporation, ELLA - CS, s.r.o., Glaukos Corporation, HOBBS MEDICAL, INC, Micro-Tech (Nanjing) Co., Ltd. and Merit Medical Systems.
| Market Value for 2023 | USD 1,468.4 million |
|---|---|
| Market Value for 2033 | USD 2,466.5 million |
| Market Forecast CAGR (2023 to 2033) | 5.30% |
| Market CAGR (2023 to 2033) | 4.7% |
|---|---|
| Market Size (2023) | USD 2,737.4 million |
| Market Size (2033) | USD 4,344 million |
| Market Value (2022) | USD 21.4 billion |
|---|---|
| Market Forecast Value (2032) | USD 34.20 billion |
| Market Expected CAGR (2022 to 2032) | 4.8% |
Explore Therapeutic Device Insights
View Reports
Non-Vascular Stents Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
